盐酸哌甲酯(Methylphenidate Hydrochloride) - 药物靶点：DAT_在研适应症：注意缺陷障碍伴多动，注意缺陷障碍，发作性睡病_专利_临床

概要

基本信息

简介盐酸哌醋甲酯是一种中枢神经系统兴奋剂，于1955年12月5日在美国首次获批上市，由诺华制药公司生产。该药物主要用于治疗嗜睡症、注意力缺陷障碍和多动症等疾病。其化学名称为甲基α-苯基-2-哌嗪乙酸酯盐酸盐，可刺激中枢神经系统，提高警觉性和注意力，从而改善症状。盐酸哌醋甲酯已被广泛应用于治疗注意力缺陷障碍和多动症等儿童和青少年常见的神经行为疾病，是一种较为安全和有效的治疗药物。

药物类型

小分子化药

别名

D-MPH、Methyl phenidylacetate、methyl phenyl(piperidin-2-yl)acetate

+ [35]

靶点

DAT

作用机制

多巴胺重摄取抑制剂

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

苏州第壹制药有限公司Novartis Pharma AG

MEDICE Arzneimittel Pütter GmbH & Co. KG

+ [14]

非在研机构

Novartis Pharmaceuticals Corp.

ALZA Corp.

Purdue Pharma LP

+ [6]

最高研发阶段批准上市

首次获批日期

美国 (1955-12-05),

注意缺陷障碍发作性睡病

最高研发阶段(中国)批准上市

特殊审评优先审评 (中国)

登录后查看时间轴

结构

分子式C14H20ClNO2

InChIKeyJUMYIBMBTDDLNG-UHFFFAOYSA-N

CAS号298-59-9

关联

510

项与盐酸哌甲酯相关的临床试验

NCT06580041 / Enrolling by invitation临床4期IIT

Precision Care for Major Depressive Disorder

This study aims to assess whether phenotyping-guided intervention selection is superior to intervention selection without phenotyping guidance (i.e., routine clinician and patient judgment regarding treatment selection) for depression.

开始日期2024-11-12

申办/合作机构

The University of California, San Francisco

NCT06431256 / Recruiting临床3期

Phase 3, Multicenter, 3-Week Fixed-dose, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy, Safety and Pharmacokinetic Study of Evening Dosed Methylphenidate Hydrochloride Extended-Release Capsules (HLD200) in Children Aged 4 to 5 Years With ADHD

This study will evaluate the efficacy, safety and pharmacokinetics of HLD200 (20 mg and 40 mg) in children aged 4 to 5 years with ADHD.

开始日期2024-09-13

申办/合作机构

Ironshore Pharmaceutical & Development, Inc.

[+1]

NCT06465641 / Not yet recruiting临床4期IIT

Effectiveness of Methylphenidate in Children and Adolescents With KBG Syndrome: An N-of-1 Series

The goal of this clinical trial] is to learn about the effect of methylphenidate in children and adolescents with KBG syndrome. The main question it aims to answer is:
• What is the effectiveness of methylphenidate on attention deficit and ADHD-related symptoms in children and adolescents with KBG syndrome?
Participants will receive multiple blocks of treatment with methylphenidate and placebo and fill out various questionnaires.

开始日期2024-09-01

申办/合作机构

Radboud University Medical Center

100 项与盐酸哌甲酯相关的临床结果

登录后查看更多信息

100 项与盐酸哌甲酯相关的转化医学

登录后查看更多信息

100 项与盐酸哌甲酯相关的专利（医药）

登录后查看更多信息

8,482

项与盐酸哌甲酯相关的文献（医药）

2024-12-01·Sleep medicine: X

Comorbidity of obstructive sleep apnea and narcolepsy: A challenging diagnosis and complex management

Review

作者: De Pieri, Marco ; Kheirandish-Gozal, Leila ; Miano, Silvia

Introduction:

Narcolepsy and obstructive sleep apnea syndrome (OSA) are relevant causes of excessive daytime sleepiness (EDS); although different for etiopathogenesis and symptoms, differential diagnosis is sometimes difficult, and guidelines are lacking concerning their management when coexisting in a same patient.

Methods:

A narrative review of the literature was realized including PubMed, Scopus and Embase, aimed to regroup studies and case reports evaluating epidemiology, clinical and instrumental features and treatment of patients presenting comorbid NT1 and OSA. Moreover, a snowball search on the pathophysiology underpinnings of the association of the two disorder was realized.

Results:

For adults, the prevalence of OSA in NT1 ranged from 24.8 % to 51.4 %. No studies were found concerning the treatment of EDS in double-diagnosis patients, but only case reports; these latter and the experience on patients with either NT or OSA suggest that modafinil, methylphenidate, pitolisant and solriamfetol are effective.

Discussion:

Adults with NT1 showed a higher prevalence of OSA compared to the general population, but the reach of the results reviewed here is limited by the retrospective design of most of the studies and by the inhomogeneous utilization of diagnostic criteria. The association with OSA is likely to be explained by the involvement of orexin in hypercapnic-hypoxic responses: a deficit of orexin may promote obstructive events during sleep. Open questions warrant further investigation, especially orexin's involvement in other sleep disorders associated with EDS, and the more appropriate treatment for the OSA-narcolepsy comorbidity.

2024-12-01·Molecular biology reports

Comparison of neuroprotective effects of a topiramate-loaded biocomposite based on mesoporous silica nanoparticles with pure topiramate against methylphenidate-induced neurodegeneration

Article

作者: Khalilzadeh, Mina ; Mir, Saeedeh ; Pari, Erfan ; Motevalian, Manijeh ; Moazam, Ashrafsadat ; Sheibani, Mohammad ; Sazegar, Mohammad Reza

BACKGROUND:

Methylphenidate (MPH) abuse has been criticized for its role in neurodegeneration. Also, a high risk of seizure was reported in the first month of MPH treatment. Topiramate, a broad-spectrum Antiepileptic Drug (AED), has been used as a neuroprotective agent in both aforementioned complications. Nanotechnology is introduced to increase desirable neurological treatment with minimum side effects. We aimed to investigate the potential neuroprotective activity of topiramate loaded on nanoparticles.

METHODS AND RESULTS:

MTT assay was performed to evaluate the cellular cytotoxicity of Mesoporous Silica Nanoparticles (MSN). Male rats were randomly divided into eight groups. Rats received an intraperitoneal (i.p) MPH (10 mg/kg) injection and a daily oral dose of topiramate (TPM, 30 mg/kg), MSN with Zn core (10 and 30 mg/kg), and MSN with Cu core (10 and 30 mg/kg) for three weeks. On day 21, a seizure was induced by a single injection of pentylenetetrazole (PTZ) to evaluate the protective effects of TPM-loaded nanoparticles on seizure latency and duration following MPH-induced neurotoxicity. Moreover, the hippocampal content of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), malondialdehyde (MDA), and the anti-oxidant enzymes (SOD, GPx, and GR) activities were assessed. Also, BAX and Bcl-2 as two main apoptotic markers were evaluated.

RESULTS:

MPH neurotoxicity was observed as a raised duration and reduced latency in PTZ-induced seizure. However, TPM-loaded MSN with Zn species (NE) treatment reduced the duration and improved the latency time. Also, NE and, somewhat, TPM-loaded MSN with Cu species (NM) administration reduced inflammatory cytokines, MDA, and Bax levels and increased activities in the rat hippocampus.

CONCLUSION:

TPM-loaded nanoparticles could be used as neuroprotective agents against MPH-induced neurodegeneration by improving seizure parameters and reducing inflammatory, oxidant, and apoptotic factors.

2024-12-01·Stem Cell Research

Generation of induced pluripotent stem cells from ADHD patients who do or do not respond to Methylphenidate treatment

Article

作者: Herms, Stefan ; Grünblatt, Edna ; Walter, Natalie Monet ; Iseli, Cedric ; Rickli, Michelle ; Ohki, Cristine Marie Yde ; Werling, Anna Maria ; Hoffmann, Per ; Rubio, Belén ; Yde Ohki, Cristine Marie ; Walitza, Susanne ; Döring, Christian

As a neurodevelopmental multifactorial disorder whose prevalence has been increasing worldwide, attention-deficit hyperactivity disorder (ADHD) is considered a public health concern. Methylphenidate (MPH) is the drug of choice for ADHD; however, not all patients respond fully to this treatment. Therefore, exploring the underlying molecular mechanisms involved in ADHD and potential novel therapeutic targets is crucial. Here, we generated induced pluripotent stem cells (iPSCs) from Peripheral Blood Mononuclear Cells (PBMCs) retrieved from four ADHD patients (two MPH responders and two non-responders) using Sendai virus. These lines might be helpful for the in vitro investigation of ADHD pathophysiology in a patient-specific manner.

189

项与盐酸哌甲酯相关的新闻（医药）

2024-10-29

·GlobeNewswire-Health Care

Praxis Bioresearch Obtains FDA Clearance On the IND Application for Its Lead Candidate PRX-P4-003 In Alzheimer’s Disease Apathy

LOS ANGELES, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Praxis Bioresearch reports that the United States Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for PRX-P4-003, a gut-activated stimulant, to treat apathy in Alzheimer’s Disease. Previously, an exploratory microdose clinical trial in healthy volunteers demonstrated successful activation of PRX-P4-003 upon oral administration, the intended therapeutic route. “Apathy remains one of the most frequently observed symptoms in the Alzheimer’s Disease with no FDA-approved therapy,” stated Jeffrey Cummings, MD, ScD, director of the Chambers-Grundy Center for Transformative Neuroscience and Professor of Brain Sciences at the University of Nevada Las Vegas, “PRX-P4-003 has chemical properties and preliminary clinical validation that support its potential to build upon the pioneering studies in treating apathy led by the NIH-funded ADMET group.” PRX-P4-003, a selectively bioavailable dopamine and norepinephrine reuptake inhibitor, is a new chemical entity discovered by Praxis Bioresearch. The compound was designed to be activated by pancreatic lipase, an enzyme that is only present in the digestive system. “This is an important milestone for us,” said Sandeep Patil, MD PhD, CEO/Cofounder of Praxis Bioresearch, “I am particularly proud of our team in successfully delivering a high-quality IND package. In the next phase of development, we are deeply committed to demonstrating the effectiveness of our compound in improving the symptoms of apathy in the clinical trials." About PRX-P4-003 PRX-P4-003 is a new chemical entity developed by Praxis Bioresearch that delivers an active isomer of fencamfamine. Fencamfamine is a Schedule IV stimulant that was originally developed and marketed by E. Merck KG, located in Darmstadt, Germany. This prodrug, unlike current stimulants such as methylphenidate and amphetamines, is designed to only be orally active potentially decreasing the risk of abuse. There is a medical need for alternatives to current Schedule II stimulant medications in neuropsychiatric indications as diversion is a significant concern. About Apathy in Alzheimer’s Disease Apathy is the most prevalent neuropsychiatric symptom of Alzheimer’s dementia, affecting nearly 71% of patients over the course of the disease. Apathy has been associated with patient suffering, caregiver distress, and excess disability. There is no approved treatment for apathy in Alzheimer’s Disease. Disclaimer: Research reported in this publication was supported in part by the National Institute of Aging of the National Institutes of Health under Award Number R44AG066378. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Contact: info@praxisbioresearch.com

临床申请

2024-10-06

·奇点网

“聪明药”可不一定真能变聪明！

*仅供医学专业人士阅读参考从几年前到现在，不少新闻都报道了“聪明药”的滥用，传说中，“聪明药”可以让人更专注，不怎么休息也能长时间保持头脑清醒和思维敏捷，所以会有学生在重要考试前夕服用。实际上，这些“聪明药”主要就是治疗注意缺陷/多动障碍（ADHD）的中枢兴奋剂类药物，例如哌甲酯和安非他明，即使前者是我国一类管制精神类药品，后者在我国尚未批准上市，也挡不住一些违规处方和代购。但是，中枢兴奋剂类药物也有相应的不良反应，包括头晕、头痛、失眠、眩晕、心悸和胃肠道反应等。甚至安非他明由于显著增加突触前多巴胺释放量，与精神疾病患者中观察到的现象一致，而存在增加精神疾病风险的担忧。在最近的《美国精神病学杂志》上，美国麦克莱恩医院的研究团队通过病例对照研究揭示，与过去一个月内未服用相比，服用安非他明与精神疾病和躁狂症风险增加168%有关，且存在剂量反应关系，高剂量（＞30mg右旋安非他明当量）与风险增加428%有关，相比之下，服用哌甲酯则与风险增加无关[1]。这项研究使用麻省总医院百瀚医疗系统（MGB）的电子医疗记录数据，纳入了2005-2019年间在麦克莱恩医院首次因精神疾病或躁狂症入院的16-35岁患者作为病例组，研究人员为每位患者匹配了2名没有精神疾病和躁狂症史，因抑郁和/或焦虑障碍入院的患者作为对照组。病例组和对照组分别纳入了1374例和2748例患者，病例组中，60.6%因精神疾病入院，28.2%因有精神疾病特征的发作性躁狂症入院，11.1%因无精神疾病特征的发作性躁狂症入院。研究筛选流程和最终入组人数在过去一个月中，有415例参与者服用过安非他明，病例组和对照组分别为204例和211例，病例组报告非处方中枢兴奋剂类药物滥用的更多，但大多数参与者仍然是通过处方获取安非他明的（病例组和对照组分别为79.4%和89.1%）。在校正了人口统计学因素、基础精神疾病、精神类药物和家族史因素后，研究人员发现，与未服用相比，过去一个月内服用安非他明与精神疾病和躁狂症风险增加168%有关，且存在剂量反应关系，低（≤15mg）、中（＞15至30mg）和高（＞30mg）剂量分别与风险增加79%、251%和428%有关。病例组与对照组在过去一个月内服用安非他明的情况和精神疾病/躁狂症风险在精神疾病和躁狂症的风险归因占比方面，任意剂量的处方安非他明为62.7%，高剂量为81.0%。研究人员还发现，在≤22岁的参与者中，安非他明的影响小于＞22岁的参与者，风险增加分别为126%和310%。在不同性别中没有这样的差异。在过去一个月内，病例组和对照组分别有37例和102例参与者服用哌甲酯，与未服用相比，服用哌甲酯与精神疾病和躁狂症的风险增加无关，参与者的哌甲酯服用剂量显著低于安非他明（平均右旋安非他明当量：哌甲酯为18.1mg，安非他明为25.2mg）。综上所述，服用安非他明与精神疾病和躁狂症的风险显著增加有关，并且风险会随着剂量的升高而升高，而哌甲酯与风险增加无关。这一结果与此前一项大型队列发现的，安非他明相比哌甲酯与精神疾病风险增加有关[2]相一致。研究人员指出，中枢兴奋剂类药物的标签上没有剂量上限，为患者开具的药物剂量主要取决于医生对病情严重程度的判断，但根据本研究的结果，精神疾病和躁狂症的风险会随药物剂量增加，需要引起注意。至于想要尝试“聪明药”的朋友，最好也还是收手吧~参考文献：[1] Moran L V, Skinner J P, Shinn A K, et al. Risk of Incident Psychosis and Mania With Prescription Amphetamines[J]. American Journal of Psychiatry, 2024: appi. ajp. 20230329.[2] Moran L V, Ongur D, Hsu J, et al. Psychosis with methylphenidate or amphetamine in patients with ADHD[J]. New England Journal of Medicine, 2019, 380(12): 1128-1138.本文作者丨应雨妍

临床结果

2024-10-02

·PRNewswire

Once-daily RELEXXII® (methylphenidate hydrochloride extended-release tablet) proudly supports Attention Deficit Hyperactivity Disorder (ADHD) Awareness Month

ALPHARETTA, Ga., Oct. 1, 2024 /PRNewswire/ -- This ADHD Awareness Month, we stand with the ADHD community. Alora Pharmaceuticals, LLC, the largest U.S. manufacturer of methylphenidate medications,1 recognizes that ADHD impacts various aspects of daily life, from school to work to personal time. This month, let's all commit to increasing awareness and understanding of ADHD while fostering a more supportive environment. ADHD is among the most prevalent neurodevelopmental disorders in children and can be a lifelong disorder, with symptoms emerging in childhood and persisting into adulthood. Recognizing the signs of ADHD is an important step in obtaining a diagnosis.2 According to the Centers for Disease Control and Prevention (CDC), approximately 10.2% of children in the U.S., ages 3 to 17, have been diagnosed with ADHD.3 According to the National Institutes of Health (NIH), the percentage of adults with ADHD is estimated to be around 4-5%.4 These statistics indicate that millions of children and adults in the U.S. are living with this condition. Medication, along with behavioral therapy, is often used in ADHD treatment.2 Stimulants, like RELEXXII ®, are fast-acting and among the most well-known and frequently utilized medications for ADHD. The CDC states that 70-80% of children with ADHD experience a reduction in symptoms when using stimulant medications.5 "Raising awareness about ADHD is vital in breaking down barriers and fostering understanding. Accurate diagnosis and effective management are crucial for improving patient outcomes and quality of life. At Alora Pharmaceuticals, we strive to provide the resources and support needed to empower individuals with ADHD to reach their full potential," stated Shannon Faught, CCO of Alora Pharmaceuticals. For more information on RELEXXII® please visit relexxii.com. For Important Safety Information visit relexxii.com/isi. For full Prescribing Information, including BOXED WARNING, visit relexxii.com/pi. For U.S. residents only. About Alora Pharmaceuticals, LLC. Alora Pharmaceuticals, LLC is the parent company of six specialty pharmaceutical and pharmaceutical manufacturing companies. Headquartered in Alpharetta, GA, Alora is the parent company of the following organizations that comprise the Alora Family of Companies: Avion Pharmaceuticals, Acella Pharmaceuticals, Osmotica Pharmaceuticals, Sovereign Pharmaceuticals, Trigen Laboratories, and Vertical Pharmaceuticals. For media inquiries or for more information about Alora's efforts to address the nationwide ADHD treatment supply shortage, please contact Alora Pharmaceuticals, LLC: 1880 McFarland Parkway, Suite 110, Alpharetta, GA 30005; 1-678-325-5189. Relexxii® is a registered trademark of Vertical Pharmaceuticals, LLC. References: 1. Data on file, Osmotica Pharmaceuticals. 2. 3. 4. 5. SOURCE Alora Pharmaceuticals , LLC WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

100 项与盐酸哌甲酯相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01296	盐酸哌甲酯	N06BA04	DB00422

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
注意缺陷障碍伴多动	中国	苏州第壹制药有限公司	1982-01-01
注意缺陷障碍	美国	Sandoz, Inc.	1955-12-05
发作性睡病	美国	Sandoz, Inc.	1955-12-05

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
疲劳	临床3期	美国	McNeil Consumer & Specialty Pharmaceuticals, Inc.	2008-02-01
实体瘤	临床3期	美国	McNeil Consumer & Specialty Pharmaceuticals, Inc.	2008-02-01
重度抑郁症	临床3期	-	Janssen, Inc.	2005-06-01
乳腺癌	临床2期	加拿大	Purdue Pharma LP	2017-10-09
认知功能障碍	临床2期	加拿大	Purdue Pharma LP	2017-10-09

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01351272 (BEAS, CTgov)	临床3期	注意缺陷障碍伴多动	41	Methylphenidate, non-retard	簾鹽繭淵鏇選選膚艱蓋(築願鏇構齋網獵構觸夢) = 簾襯餘構簾餘鑰醖膚醖網蓋齋範觸壓鬱鬱蓋願 (築窪窪蓋鏇築遞鏇壓鬱, 獵選鏇鬱願憲窪鏇鹽窪 ~ 鹽構夢夢糧選窪襯鏇鬱) 更多	-	2024-08-15
NCT03326245 (CTgov)	临床1期	-	25	Oral Placebo+Intravenous methylphenidate (Arm B: Oral Placebo Followed by Intravenous Methylphenidate)	壓窪鬱願膚遞壓襯壓範(衊鏇夢憲願艱廠範繭醖) = 餘築簾壓鹹艱襯願構遞願襯齋願簾願鏇膚顧獵 (遞網膚廠選選壓艱壓夢, 選選鹹範鹹艱鏇簾襯遞 ~ 淵獵廠淵願膚鑰構遞糧) 更多	-	2024-05-28
				Intravenous Placebo (Arm C: Oral Placebo Followed by Intravenous Placebo)	壓窪鬱願膚遞壓襯壓範(衊鏇夢憲願艱廠範繭醖) = 襯夢製鑰餘願願顧鹽齋願襯齋願簾願鏇膚顧獵 (遞網膚廠選選壓艱壓夢, 衊餘範鬱簾觸範壓廠鏇 ~ 餘範廠糧獵醖鹽糧膚鬱) 更多
NCT02346201 (ADMET 2, Pubmed \| Int Psychogeriatr)	临床3期	痴呆	167	Methylphenidate	膚艱廠網膚憲製製範壓(膚獵廠壓積築艱糧選簾) = Utility improved with methylphenidate treatment as there was a group by time interaction 憲蓋構膚鏇築衊遞願築 (範夢顧製網簾鹹廠齋醖 )	积极	2023-11-01
				Placebo
NCT02473185 (Pubmed \| BMC Psychiatry)	临床4期	注意缺陷障碍伴多动	40	Methylphenidate 20 mg immediate release	糧壓獵願觸壓餘繭積築(蓋夢簾糧鑰範廠簾鬱鹹) = 鹽鬱膚顧餘壓鬱窪衊鬱範鹽齋範齋獵窪壓構廠 (範繭築齋鑰網糧鑰繭顧 )	积极	2023-10-17
				Placebo	糧壓獵願觸壓餘繭積築(蓋夢簾糧鑰範廠簾鬱鹹) = 鹽衊窪壓鏇夢簾簾構夢範鹽齋範齋獵窪壓構廠 (範繭築齋鑰網糧鑰繭顧 )
NCT04987762 (CTgov)	临床4期	注意缺陷障碍伴多动	103	Adhansia XR	製鹽鏇醖鹹廠觸製鏇獵(願憲築築窪淵憲製範構) = 窪範鑰選範衊鹹顧鹽壓淵鹹鑰製鬱蓋簾襯蓋襯 (襯壓構簾鏇窪願築鹹繭, 簾遞膚鬱糧鬱廠膚製餘 ~ 鑰繭顧築壓壓衊蓋鬱艱) 更多	-	2023-08-22
NCT04507204 (RE-DAX, CTgov)	临床4期	注意缺陷障碍伴多动	267	Adhansia XR (Adhansia XR)	襯窪齋選蓋鬱窪範鹽範(廠壓蓋糧顧構遞遞壓齋) = 衊夢獵憲壓積遞範繭壓齋觸構艱積夢遞觸艱構 (鹽積醖範選鬱蓋構顧襯, 製襯鬱糧衊廠構製構夢 ~ 簾廠簾鑰遞鏇夢繭鏇積) 更多	-	2023-07-27
				Concerta (Concerta)	夢構獵廠鏇繭觸願繭顧(鑰鑰壓選觸壓夢鏇觸鑰) = 憲艱顧網觸範鹹願鬱製夢蓋膚選餘觸鹹糧餘範 (憲糧鏇醖鏇襯觸廠顧願, 鹽襯醖構膚齋顧獵範膚 ~ 鹹餘繭鏇鹹獵廠鬱膚憲) 更多
NCT02346201 (ADMET2 \| ADMET 2, CTgov)	临床3期	阿尔茨海默症 \| 冷漠	200	Methylphenidate (Methylphenidate)	餘遞蓋構憲獵積鹽艱積(範憲構製選網顧繭齋觸) = 鏇鏇鬱糧獵觸襯壓積鬱遞遞構鑰齋蓋獵鑰夢製 (願築淵醖遞壓淵積鏇憲, 構窪壓積簾淵願憲膚鏇 ~ 鹹鹹鹽鹹鬱範廠鏇顧衊) 更多	-	2023-06-13
				Placebo (Placebo)	餘遞蓋構憲獵積鹽艱積(範憲構製選網顧繭齋觸) = 憲憲製餘憲簾選積壓製遞遞構鑰齋蓋獵鑰夢製 (願築淵醖遞壓淵積鏇憲, 鹽鏇廠夢觸觸網築膚構 ~ 鬱簾構觸醖醖壓醖繭衊) 更多
NCT00424099 (CTgov)	临床2/3期	疲劳 \| 晚期癌症	197	Methylphenidate (MP) (Methylphenidate (MP) + Nursing Telephone Intervention (NTI))	繭繭淵憲淵鬱範願廠廠(網窪壓遞積鑰鏇鑰廠鹹) = 憲艱憲構網選鬱願簾願願構觸廠憲鬱積積淵醖 (簾鑰淵襯製窪顧選餘蓋, 範構觸醖構廠構廠壓觸 ~ 繭製淵廠鹽夢鏇築築範) 更多	-	2023-06-01
				Methylphenidate (MP) (Methylphenidate (MP) + Control Telephone Intervention (CTI))	繭繭淵憲淵鬱範願廠廠(網窪壓遞積鑰鏇鑰廠鹹) = 夢選齋艱衊觸糧醖壓繭願構觸廠憲鬱積積淵醖 (簾鑰淵襯製窪顧選餘蓋, 築艱遞蓋選鹽廠鹹鬱鬱 ~ 襯窪觸獵鬱膚窪廠遞願) 更多
NCT02153944 (CTgov)	临床4期	焦虑症	142	Methylphenidate (Behavioral: Drug Challenge With Methylphenidate)	遞夢窪鑰鏇願齋繭醖鹹(簾選餘廠繭獵鹹顧鏇齋) = 簾鹹艱壓壓獵獵遞鬱繭構積窪顧艱鹹繭鹽選築 (鹹簾夢壓觸獵鹹鹽淵製, 壓選衊衊簾醖衊廠築膚 ~ 夢鹹構製製範鬱築憲遞) 更多	-	2023-04-11
				Placebo (Behavioral: Drug Challenge With Placebo)	遞夢窪鑰鏇願齋繭醖鹹(簾選餘廠繭獵鹹顧鏇齋) = 願衊襯鏇淵廠遞鹹顧顧構積窪顧艱鹹繭鹽選築 (鹹簾夢壓觸獵鹹鹽淵製, 壓觸鏇壓蓋窪蓋餘範衊 ~ 淵簾糧製齋壓網窪醖網) 更多
Pubmed	N/A	注意缺陷障碍伴多动	-	Methylphenidate	膚鬱憲觸餘夢窪衊觸廠(夢艱願簾願鑰範積鬱積) = 築膚獵襯觸鑰廠襯夢願齋構築範餘蓋獵衊築簾 (襯蓋鬱淵願艱襯鬱範選 )	-	2023-03-27